吡唑并[1,5-a]吡啶-3-羧酸 | 16205-46-2

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 中文名称: 吡唑并[1,5-a]吡啶-3-羧酸
• 中文别名: 吡唑[1,5-a]吡啶-3-羧酸；吡唑[1,5-A]吡啶-3-甲酸
• 英文名称: pyrazolo[1,5-a]pyridine-3-carboxylic acid
• CAS: 16205-46-2
• 化学式: C₈H₆N₂O₂
• mdl: MFCD00229214
• 分子量: 162.148
• InChiKey: HRSDPDBQVZHCRC-UHFFFAOYSA-N

物化性质

• 熔点：
  199 °C
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	Pyrazolo[1 5-a]pyridine-3-carboxylicacid 97% Material Safety Data Sheet
Synonym:
CAS:	16205-46-2

Section 1 - Chemical Product MSDS Name:Pyrazolo[1 5-a]pyridine-3-carboxylicacid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
16205-46-2	Pyrazolo[1,5-a]pyridine-3-carboxylic a	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 16205-46-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 207 - 209 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6N2O2
Molecular Weight: 162.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 16205-46-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Pyrazolo[1,5-a]pyridine-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 16205-46-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 16205-46-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 16205-46-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  吡唑并[1,5-a]吡啶-3-羧酸 在 lithium aluminium tetrahydride 、 草酰氯 作用下， 以 乙醚 为溶剂， 反应 8.5h， 生成 FAUC 113
  参考文献：
  名称：

  Azaindole derivatives with high affinity for the dopamine D4 receptor: Synthesis, ligand binding studies and comparison of molecular electrostatic potential maps

  摘要：

  Piperazinylmethyl substituted pyrazolo[1,5-a]pyridines and related heterocycles were synthesized and found to recognize selectively the dopamine D4 receptor. For the most potent derivative 10d a Ki value of 2.0 nM was observed. SAR studies including the comparison of molecular isopotential surfaces were performed. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00692-1
• 作为产物：
  描述：

  吡唑并[1,5-A]吡啶-3-甲酸乙酯 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 吡唑并[1,5-a]吡啶-3-羧酸
  参考文献：
  名称：

  通过取代铰链结合剂部分发现有效的集落刺激因子1受体抑制剂

  摘要：

  肿瘤相关的巨噬细胞（TAM）主要与肿瘤的生长有关。集落刺激因子1受体（CSF1R）充当TAM存活和分化的关键调节剂，并且是癌症治疗的分子靶标。本文中，通过铰链结合部分的替代策略鉴定了新型CSF1R抑制剂。咪唑并[1,2- a ]吡啶（49）或吡唑并[1,5- a ]吡啶（50）作为铰链粘合剂的引入在酶法测定中对CSF1R在10 nM抑制率分别为87％和82％。 IC 50在MNFS60单元中分别为25 nM和27 nM的值。这些衍生物显着抑制细胞中的CSF1R磷酸化。我们的方法可以用作发现新型激酶抑制剂的策略。

  DOI：

  10.1016/j.ejmech.2021.113298

文献信息

• Optimized scale up of 3-pyrimidinylpyrazolo[1,5-a]pyridine via Suzuki coupling; a general method of accessing a range of 3-(hetero)arylpyrazolo[1,5-a]pyridines
  作者：Paul A. Bethel、Andrew D. Campbell、Frederick W. Goldberg、Paul D. Kemmitt、Gillian M. Lamont、Abid Suleman

  DOI：10.1016/j.tet.2012.04.094

  日期：2012.7

  an improved synthesis of 3-(hetero)aryl pyrazolo[1,5-a]pyridines (such as 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-a]pyridine (8)) via an optimized synthesis and Suzuki coupling of 3-pyrazolo[1,5-a]pyridine boronic ester 10. These conditions are applicable to both high throughput chemistry and large scale synthesis of these medicinally important compounds. The scope of this chemistry has been further

  我们已经开发出3-（杂）芳基吡唑并[1,5- a ]吡啶（例如3-（2,5-二氯嘧啶-4-基）吡唑并[1,5- a ]吡啶（8）的合成方法。）通过优化的合成方法和3-pyrazolo [1,5- a ]吡啶硼酸酯10的Suzuki偶联。这些条件适用于这些医学上重要的化合物的高通量化学和大规模合成。该化学反应的范围已进一步扩展到包括新型硼酸酯3-（4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基）-6,7的合成和偶联-二氢-5 H-吡唑并[5,1- b ] [1,3]恶嗪（43）。
• Azabicyclic compounds for the treatment of disease
  申请人：——

  公开号：US20030232853A1

  公开（公告）日：2003-12-18

  The invention provides compounds of Formula I: 1 wherein Azabicyclo is 2 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &agr;7 is known to be involved.

  这项发明提供了Formula I的化合物： 其中Azabicyclo是 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对已知涉及α7的药物具有用处。
• Substituted 7-aza[2.2.1]bicycloheptanes for the treatment of disease
  申请人：——

  公开号：US20030105089A1

  公开（公告）日：2003-06-05

  The invention provides compounds of Formula I: 1 which may be in the form of pharmaceutical acceptable salts or compositions, are useful in treating diseases or conditions in which &agr;7 nicotinic acetylcholine receptors (nAChRs) are known to be involved.

  这项发明提供了Formula I的化合物： 1 这些化合物可以是药用可接受的盐或组合物的形式，对治疗涉及α7尼古丁型乙酰胆碱受体(nAChRs)的疾病或症状是有用的。
• Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
  申请人：——

  公开号：US20030236264A1

  公开（公告）日：2003-12-25

  The invention provides compounds of Formula I: 1 These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat conditions or diseases in which &agr;7 is known to be involved.

  这项发明提供了I式化合物： 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对于治疗已知涉及α7的疾病或病症的药物非常有用。
• Development of Potent Serotonin-3 (5-HT3) Receptor Antagonists. II. Structure-Activity Relationships of N-(1-Benzyl-4-methylhexahydro-lH-1,4-diazepin-6-yl)carboxamides.
  作者：Hiroshi HARADA、Toshiya MORIE、Yoshimi HIROKAWA、Hideo TERAUCHI、Iwao FUJIWARA、Naoyuki YOSHIDA、Shiro KATO

  DOI：10.1248/cpb.43.1912

  日期：——

  reflex in rats are described. Heteroaromatic rings such as pyrrole, thiophene, furan, pyridine, pyridazine, 1,2-benzisoxazole, indole, quinoline, and isoquinoline rings showed weak 5-HT3 receptor antagonistic activity. Within this series, use of the 1H-indazole ring as an aromatic moiety led to a substantial increase of the activity; the 1H-indazolylcarboxamides 54, 57, 97, and 102 showed potent 5-HT3

  我们对4-氨基-5-氯-2-乙氧基苯甲酰胺的研究导致发现N-（1,4-二甲基六氢-1H-1,4-二氮杂-6-6基）苯甲酰胺9和1-苄基-4 -甲基六氢-1H-1,4-二氮杂analogue类似物10是有效的血清素3（5-HT3）受体拮抗剂。描述了结构和活性关系（SAR）研究9和10的芳香核对大鼠von Bezold-Jarisch反射的抑制作用。杂芳族环，如吡咯，噻吩，呋喃，吡啶，哒嗪，1,2-苯并恶唑环，吲哚，喹啉和异喹啉环显示弱的5-HT3受体拮抗活性。在这个系列中，使用1H-吲唑环作为芳族部分会导致活性的大幅提高。1H-吲唑基羧酰胺54、57、97和102显示出有效的5-HT3受体拮抗活性。